Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT03200327
Other study ID # AOIGCSMERRI/2016/RdT01
Secondary ID
Status Terminated
Phase N/A
First received
Last updated
Start date December 18, 2017
Est. completion date January 1, 2022

Study information

Verified date January 2022
Source Centre Hospitalier Universitaire de Nimes
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The investigators anticipate a reduced risk of post-operational de novo stress urinary incontinence following surgery for vaginal sacrospinofixation, associated with reduced costs, comparable functional and anatomical efficacy and no increase in morbidity and rate of dyspareunia with the new treatment


Recruitment information / eligibility

Status Terminated
Enrollment 55
Est. completion date January 1, 2022
Est. primary completion date March 1, 2021
Accepts healthy volunteers No
Gender Female
Age group 50 Years to 80 Years
Eligibility Inclusion Criteria: - The patient must have given their free and informed consent and signed the consent form - The patient must be a member or beneficiary of a health insurance plan - Patient must be available for 12 month follow-up - Patient is =50 and <80 years old - Patient has pelvic prolapse stage 2 or above according to international POP-Q score, concerning the anterior and apical compartments, justifying surgical treatment - Patients not having preoperational stress urinary incontinence or having mild stress urinary incontinence not causing significant functional problems (response <2 to question 17 of PFDI-20 questionnaire). It is possible that patients with hidden stress urinary incontinence will be recruited Exclusion Criteria: - The subject is participating in an interventional study, or is in a period of exclusion determined by a previous study - The patient is under safeguard of justice or state guardianship - The subject refuses to sign the consent - Patient with communication issues preventing comprehension of information and administration of questionnaires - Pelvic prolapse not affect anterior and apical compartments, regardless of stage - Patient with preoperative dyspareunia (patients with mild sexual discomfort related to prolapse may be included - Patient presents with preoperative stress urinary incontinence responsible of significant functional incapacity (response =2 to question 17 of PFDI-20 questionnaire). - Indication for concomitant suburethral sling - Patient with previous history of surgery for stress urinary incontinence - Indication of concomitant perineorrhaphy surgery with or without myorrhaphy (in both groups). - Contra-indication for general anesthetic - Current urinary infection - Current vaginal infection

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
promontofixation
reconstruction of cystoceles using a subvesical prosthesis
sacrospinofixation
Utero-vaginal suspension by bilateral anterior sacrospinofixation using the vaginal route

Locations

Country Name City State
France CHU de clermont-Ferrand clermont-Ferrand
France CHU de Lille Lille
France HFME - Hospices Civils de Lyon Lyon
France CHU de Montpellier Montpellier
France Clinique Beau-Soleil Montpellier
France CHU Nimes Nîmes

Sponsors (1)

Lead Sponsor Collaborator
Centre Hospitalier Universitaire de Nimes

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Compare the rate of de novo problematic stress urinary incontinence, operable or not, between groups response = 2 to question 17 of PFDI-20 questionnaire 12 months after intervention
Secondary De novo dyspareunia rate the dyspareunia between groups = 2 to question 11 of the PISQ-IR questionnaire. 12 months after the initial intervention
Secondary Quality of sexual life between groups PISQ-IR questionnaire. 12 months after the initial intervention
Secondary Re-intervention for suburethral band (BSU) in de novo SUI between groups binary: yes/no. up to 12 months after the initial intervention
Secondary Compare anatomical prolapse symptoms between groups POP-Q questionnaire at 6 weeks and 12 months after intervention
Secondary Compare functional prolapse symptoms between groups PFDI-20 questionnaire at 6 weeks and 12 months after intervention
Secondary Compare quality of life associated to pelvic floor issues between groups PFIQ questionnaire at 6 weeks and 12 months after intervention
Secondary Compare general quality of life between groups SF12 questionnaire at 6 weeks and 12 months after intervention
Secondary Compare global satisfaction between groups PGI-I questionnaire at 6 weeks and 12 months after intervention
Secondary Compare perioperational morbidity between groups complication assessed as stage =2 on Clavien-Dindo classification, or according to the ICS/IUGA classification. at 6 weeks and 12 months after intervention
Secondary Compare direct and indirect costs of the 2 interventions 12 months after intervention
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06404931 - Transvaginal Human Acellular Dermal Matrix for Prolapse Treatment Phase 2
Completed NCT03077490 - Comparison of Single Versus Multicenter Outcomes for Pelvic Organ Prolapse Repair Using a Mesh-capturing Device
Recruiting NCT03947164 - iMEA : Comparison of Micro-innervation and Muscle Microstructure of the Anal Levator Muscle Between Patients With Urogenital Prolapse and Those Who Are Asymptomatic N/A
Active, not recruiting NCT05571072 - Opioid Use After Urogynecologic Procedures: Using a Predictive Calculator N/A
Completed NCT04178473 - Total Versus Subtotal Abdominal Hysterectomy at Time of Abdominal Sacrocolpopexy N/A
Completed NCT03534830 - A Novel Assay for Predicting Surgical Outcomes in Pelvic Organ Prolapse
Completed NCT03772015 - The Change in Vaginal Axis on MRI After Uterus Preserving Laparoscopic Lateral Mesh Suspension
Completed NCT05463081 - Clinical Trial of "Magic Gyno" Laser Device N/A